United States: FDA Issues Draft Memorandum Of Understanding For 503A Drug Compounding

Included in the flurry of guidance documents recently issued by the FDA concerning human drug compounding is a long-awaited document of great importance to mail-order pharmacy compounders and entities that rely on interstate distribution of prescription compounded drugs—a Draft Memorandum of Understanding (MOU) between the FDA and each of the 50 states. As previously discussed, this MOU has been the subject of controversy since section 503A of the FFDCA was first enacted in 1997 and this controversy again took center stage following enactment of the DQSA in 2013.

The controversy arises from a key provision of Section 503A of the FFDCA that limits the amount of compounded prescriptions a pharmacy is permitted to ship across state lines. Specifically, unless the pharmacy is located in a state that has entered into an MOU with the FDA, Section 503A of the FFDCA prohibits a pharmacy from dispensing or distributing more than five percent of the pharmacy's total prescription orders to patients outside of the state in which the pharmacy is located. This is often referred to as the "5% Rule." More specifically, Section 503A states that drugs compounded by a traditional compounding pharmacy only qualify for exemptions from adequate directions for use, new drug application requirements/approval and cGMP requirements if, among other things, one of the following conditions is met:

  • The drugs are compounded in a state that has entered into an MOU with the FDA that addresses the distribution of "inordinate amounts" of compounded drug products interstate and provides for appropriate investigation by a state agency of complaints relating to compounded drug products distributed outside such state; or
  • If the drugs are compounded in a state that has not entered into an MOU, the drugs are compounded in quantities that do not exceed five percent of the total prescription drug orders dispensed or distributed by the pharmacy or physician.

As originally enacted, Section 503A required the FDA to consult with the National Association of Boards of Pharmacy (NABP) to develop a standard MOU for use by the states in lieu of 50 separate MOUs. In January 1999, the FDA, in consultation with the NABP, published a draft MOU in the Federal Register (1999 MOU) that generated over 6,000 comments. However, shortly after publication of the 1999 MOU, the constitutionality of Section 503A was called into question and the FDA never finalized the 1999 MOU.

The DQSA settled the constitutional uncertainty that had delayed finalization of the 1999 MOU, and in Draft Guidance issued pursuant to the DQSA's modification to Section 503A, the FDA indicated that the FDA intended to publish a new draft of the MOU. Interestingly, the FDA also addressed the MOU and the 5% Rule at the Inter-Governmental Working Meeting on Pharmacy Compounding, during which Dr. Jane Axelrad, Associate Director for Policy at the FDA's Center for Drug Evaluation and Research and a key player in compounding pharmacy regulation, prepared a presentation specifically addressing the topic and issues that had been left unsettled in 1999, such as how the FDA should define "inordinate amounts" in the MOU and whether the restrictions on interstate distribution should account for contiguous states. This meeting was with representatives from various state boards of pharmacy and the NABP. The recently released Draft MOU has provided some clarity on some of these issues while remaining silent on others.

Under the Draft MOU, a pharmacist, pharmacy or physician distributes an "inordinate amount" of compounded human drug products interstate if the number of units of compounded human drug products distributed interstate during any calendar month is equal to or greater than 30 percent or more of its total number of compounded and non-compounded drug products—up from the 20 percent ratio included in the 1999 MOU. The 30 percent amount does not include prescriptions dispensed to a patient or his agent who then carries the compounded drug across state lines. Noticeably absent here is any accommodation for the distribution of compounded human drugs among contiguous states. Additionally, a note under the definition of the term "distribution" in the appendix of the Draft MOU states that the MOU "will not alter" Section 503A requirements that a compounder obtain a prescription for an individually identified patient in order to qualify for exemptions under the FFDCA. This provision seems somewhat at odds with Section 503A provisions allowing drug compounding in limited quantities before the receipt of a valid prescription in certain circumstances.

The Draft MOU provides that a state agency will conduct an "appropriate investigation" of complaints concerning compounded drugs distributed interstate and spells out six requirements for a state to investigate complaints about compounded drugs that were distributed across state lines:

  1. The "appropriate agencies" of the state will investigate complaints received relating to human drug products compounded by a pharmacist, pharmacy or physician located within the state and distributed outside the state. The Draft MOU allows for the pharmacy board or "other appropriate state agency" and the state medical licensing board or other state agency to cooperate in investigating complaints involving overlapping jurisdiction.
  2. Complaints to be investigated will include reports received by the state concerning adverse drug experiences or product quality issues that, if left uncorrected, could lead to potential public health risks or safety concerns.
  3. Any investigation conducted by the state must include (1) determining whether there is a public health risk or safety concern associated with the compounded product, and (2) confirming that any risk or safety concern is sufficiently kept in check so as to eliminate any ongoing risk to the public.
  4. If the state's investigation of the complaint concludes the complaint is valid, the state will take "appropriate action" to ensure that the relevant person or entity that compounded the drug at issue "determines the root cause of the problem ... and undertakes sufficient corrective action" to eliminate any public health risk, including the risk of future complaints. The Draft MOU does not provide additional detail or guidance as to what constitutes "appropriate action" or "sufficient corrective action."
  5. The state will notify the FDA within 72 hours of receiving any such complaint that involves a public health risk or immediate safety concern. The notification must include the state's initial assessment of the complaint's validity and a description of any actions the state has taken or plans to take to address the complaint.
  6. The state will maintain records of the complaint, the investigation and any response or action taken. The state must maintain records for at least three years.

The Draft MOU also requires the state to take certain actions in connection with the distribution of inordinate amounts of compounded drugs:

  • The state agrees to review compounding records during inspections to determine whether the compounder is distributing inordinate amounts of compounded drugs interstate.
  • The state will notify the FDA within seven days of identifying a compounder that has distributed inordinate amounts of compounded drugs interstate.
  • The state "will take action" regarding any compounder that distributes an inordinate amount interstate. Such action can include a warning letter, enforcement action, suspension, revocation of a license or any other action consistent with state law. The Draft MOU also empowers the FDA to take action.

The Draft MOU mandates that when a state submits information to the FDA concerning complaints or distribution of inordinate amounts of compounded drugs, certain minimum information be included:

  • The complainant's name and contact information, in the case of a complaint;
  • The name and address of the pharmacist/pharmacy/physician that is the subject of the complaint or distribution of inordinate amounts;
  • A description of the complaint, or of the evidence indicating that the compounder distributed inordinate amounts, including a description of any compounded drug that is the subject of the complaint or distribution;
  • The state's initial assessment of the validity of the complaint; and
  • A description and the date of any actions the state has taken to address the complaint or the distribution of inordinate amounts of compounded drugs.

The Draft MOU also provides that the state and the FDA may need to execute additional agreements or to commission certain officials before the FDA can share information that is protected from public disclosure. Such agreement or commissioning terms would govern sharing certain kinds of information:

  • Confidential commercial information that would be protected from public disclosure under Exemption 4 of the Freedom of Information Act (FOIA);
  • Personal privacy information that would be protected from disclosure under Exemption 6 or 7(C) of FOIA; or
  • Information that is otherwise protected from public disclosure from other federal statutes and regulations.

The Draft MOU provides that the state and the FDA recognize that each retains its statutory and regulatory authority. It also specifies that it does not restrict either the state or the FDA (or any other federal agency) from taking appropriate enforcement action to ensure compliance with applicable statutes and regulations. Under the terms of the Draft MOU, it will continue until terminated by either party and the FDA can terminate if the state does not adhere to the MOU.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions